GL Pharm Tech to Absorb Wholly-Owned Subsidiary GL Pharma
지엘팜텍
204840
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=583
Risk-adjusted indicator based on 583 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Merger Ratio: 1.0000000 (GL Pharm Tech) : 0.0000000 (GL Pharma)
- • GL Pharma 2025 Revenue: 21.19B KRW
3 more figures — Starter & Pro plans
AI Analysis Summary
GL Pharm Tech Corp. has decided to absorb its wholly-owned subsidiary, GL Pharma Co., Ltd., through a small-scale, non-capital increase merger. The merger ratio is 1.0000000:0.0000000, with no new shares or cash payouts. GL Pharma reported 2025 revenue of 21.19B KRW, operating profit of 1.02B KRW, and net income of 628.41M KRW. This internal restructuring aims to enhance management efficiency and is not expected to have a significant financial or operational impact on GL Pharm Tech, as it already owns 100% of GL Pharma. The merger is scheduled for July 31, 2026.
Risk Factors
Pro plan
Access Full Korean Market Signal Analytics
✔ AI-parsed DART filing classification & scoring
✔ Real-time event impact indicators
✔ Price reaction & historical pattern data
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.